沃脉德资本OrbiMed筹措7亿3千万美元投资生物技术产业
沃脉德资本顾问公司。 601列克星敦大道，54日楼。 纽约，NY 10022电话：212.739.6400•传真：212.739.6444
2013年10月31日-沃脉德资本是一家领先的投资公司，专注于医疗保健行业，该基金的投资者包括一些最大的捐赠基金，基金会，主权财富基金和金融机构全球。其投资于医疗保健部门的各个阶段和行业，专注于生物制药，医疗器械和诊断公司。今天，进行了价值达7亿3千5百万美元的第五轮投资，公司初步预计将资助大约30个公司的研发项目，每个项目资助额度大约为1000万美元到5千万美元。这也表明OrbiMed公司对生物技术产业投资开始继续加码。
沃脉德资本的合伙人，全球私募股权投资部联席主管，卡尔·戈登说：“这是一个激动人心的时刻推出我们的下一个基金，鉴于新的FDA药品审批的结合率很高，一个充满活力的IPO窗口，并加速整个生命科学投资公司的创新水平。
““我们正在寻求新的医疗保健创新的整个生物制药，设备诊断和医疗保健IT在发展阶段",乔纳森·西尔弗斯坦，沃脉德资本合伙人兼联合主管全球的私募股权投资。 “这个新基金将利用沃脉德资本的全球平台，现在包括超过跨医疗公开上市的股票，私募股权，特许权使用费和全球范围内投资超过800亿美元的80名员工信贷的机会。
“关于沃脉德资本沃脉德资本是一家领先的投资公司，专门向保健行业，有超过8亿美元在所管理的资产。 沃脉德资本投资在全球医疗保健公司，从创投初创企业到大型跨国公司。 沃脉德资本超过80名员工的团队管理一系列的私募股权基金，公众股权基金，特许权使用费/债务资金及其他投资。 沃脉德资本维持其总部设在纽约市，在旧金山设有办事处，上海，孟买和荷兹利亚。沃脉德资本作为致力于向保健行业最大的投资公司之一，目的是资本供应商的选择，带来所需的全球资源，是一个特殊的建设的长期合作伙伴世界一流的医疗保健公司。
www.OrbiMed.com。联系W.卡特Neild，CFA电话：(212)739.6400电子邮件 NeildC@OrbiMed.comwww.OrbiMed.com
OrbiMed Advisors LLC. 601 Lexington Avenue, 54
th
Floor. New York, NY 10022 • Phone: 212.739.6400 • Fax: 212.739.6444
OrbiMed Launches $735 Million Venture Capital Fund
NEW YORK, October 31, 2013 – OrbiMed, a leading investment firm focused on the healthcare sector, today
announced the closing of its next venture capital fund, OrbiMed Private Investments V, LP, with just over $735
million in commitments, including approximately $36 million from the GENEral Partner. Investors in the fund
include some of the largest endowments, foundations, sovereign wealth funds and financial institutions
globally.
Consistent with its predecessor funds, the new fund will invest in all stages and sectors of the healthcare
industry, with a focus on biopharmaceutical, medical device, and diagnostics companies located in North
America and Europe. The new fund is expected to invest in approximately 30 portfolio companies in amounts
generally ranging from $10 million to $50 million.
Carl Gordon, a Partner at OrbiMed and Co-Head of Global Private Equity, noted, “This is an exciting time to
launch our next fund, given the combination of the high rate of new FDA drug approvals, a vibrant IPO
window, and the accelerating level of innovation from companies across the life sciences investment
universe.”
“We are seeking novel healthcare innovations across biopharma, devices, diagnostics and healthcare I.T. at any
stage of development,” commented Jonathan Silverstein, also an OrbiMed Partner and Co-Head of Global
Private Equity. “This new fund will leverage OrbiMed’s entire global platform, which now includes more than
80 employees globally investing over $8 billion across healthcare public equities, private equities, royalties and
credit opportunities.”
About OrbiMed
OrbiMed is a leading investment firm dedicated exclusively to the healthcare sector, with over $8 billion in
assets under management. OrbiMed invests globally across the spectrum of healthcare companies, from
venture capital start-ups to large multinational companies. OrbiMed’s team of more than 80 employees
manages a series of private equity funds, public equity funds, royalty/debt funds and other investment
vehicles. OrbiMed maintains its headquarters in New York City, with additional offices in San Francisco,
Shanghai, Mumbai and Herzliya.
As one of the largest investment firms dedicated to the healthcare sector, OrbiMed seeks to be a capital
provider of choice, bringing the global resources required to be an exceptional long-term partner for building
world-class healthcare companies. www.OrbiMed.com.
Contact
W. Carter Neild, CFA
Phone (212) 739.6400
Email NeildC@OrbiMed.com
www.OrbiMed.com
